Welcome to our dedicated page for Pediatrix Medical Group news (Ticker: MD), a resource for investors and traders seeking the latest updates and insights on Pediatrix Medical Group stock.
Pediatrix Medical Group, Inc. (NYSE: MD) is a physician-led provider of services for women, babies and children, with specialties in obstetrics, maternal-fetal medicine, neonatology and multiple pediatric subspecialties. News about MD stock frequently centers on its financial performance, portfolio management decisions and clinical leadership in neonatal and pediatric care.
Investors following Pediatrix news will see regular quarterly earnings releases that discuss net revenue, net income, Adjusted EBITDA and Adjusted EPS, along with details on same-unit revenue trends, patient volumes, reimbursement-related factors, payor mix and hospital contract administrative fees. These updates often explain how hospital-based and office-based patient services, particularly neonatology services and neonatal intensive care unit (NICU) days, influence the company’s results.
Pediatrix also issues news on strategic and capital allocation actions, such as the authorization of a share repurchase program of up to a specified dollar amount of its outstanding common stock. Such announcements describe the intended use of the program, its term and the flexibility the company retains to adjust or discontinue repurchases. Board and governance developments, including the appointment of independent directors with extensive pediatric health care experience, are disclosed through press releases and related SEC filings.
Beyond financial and governance updates, Pediatrix highlights its role in research, education and quality improvement. News items include information about NEO: The Conference for Neonatology, a long-running educational meeting that addresses advancements and best practices in neonatal care, and about the activities of the Pediatrix Center for Research, Education, Quality and Safety. Readers who monitor MD news can track how these clinical and educational initiatives align with the company’s hospital-based neonatology and pediatric subspecialty services. For ongoing coverage, this page aggregates company press releases and related market-moving updates.
Pediatrix Medical Group (NYSE: MD) will host the 47th annual NEO: The Conference for Neonatology in Las Vegas, Feb. 25–27, 2026. The event gathers neonatal‑perinatal experts for sessions on clinical advances, neonatal POCUS training, ethics, respiratory care, nutrition, and accredited continuing education credits.
Pediatrix Medical Group (NYSE: MD) reported Q4 2025 results with net revenue $493.8M, net income $33.7M ($0.40 diluted) and Adjusted EBITDA $65.8M. For full-year 2025, revenue was $1.91B, net income $165.4M and Adjusted EBITDA $275.6M. Cash was $375.2M at year-end and the company repurchased $64.0M of shares in Q4.
Preliminary 2026 outlook targets Adjusted EBITDA $280M–$300M. Management cited same-unit revenue growth of 4.0% and higher variable practice incentive compensation as a headwind to margins.
Pediatrix Medical Group (NYSE: MD) will host an investor conference call and webcast on Thursday, February 19, 2026 at 9:00 a.m. ET to discuss results of operations for the quarter ended December 31, 2025. A detailed press release will be issued the morning of February 19, 2026 before markets open. The webcast will be available at the company investor website.
Pediatrix Medical Group (NYSE: MD) reported Q3 2025 results with net revenue $492.9M, net income $71.7M (diluted EPS $0.84) and Adjusted EBITDA $87.3M. Adjusted EPS was $0.67. Management raised full-year 2025 Adjusted EBITDA guidance to $270M–$290M. Q3 results reflected higher same-unit reimbursement (+7.6%) and same-unit revenue growth of 8.0%, partially offset by non-same unit practice dispositions. Cash and equivalents were $340.1M, total debt $602M, and operating cash from continuing operations was $138.1M in Q3. The company used cash for $20.9M share repurchases and $19.2M of acquisitions.
Pediatrix Medical Group (NYSE: MD) will host an investor conference call and webcast on Monday, November 3, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2025. A detailed press release will be issued the morning of November 3, 2025 before markets open.
The live webcast will be accessible via Pediatrix’s investor site at www.pediatrix.com/investors.
Pediatrix Medical Group (NYSE:MD) has announced a significant $250 million share repurchase program authorized by its Board of Directors. The program, which has a three-year term, demonstrates the company's confidence in its financial position, highlighted by strong cash flow, healthy cash balances, and low debt levels.
CEO Mark S. Ordan emphasized that the company will implement the program opportunistically while evaluating other strategic cash deployment options. The repurchases may be executed through private negotiations or open market transactions, following Rule 10b5-1 and/or Rule 10b-18 guidelines, with timing and volume dependent on market conditions and other factors.
Pediatrix Medical Group (NYSE:MD) reported strong Q2 2025 financial results, with earnings of $0.46 per share and adjusted EPS of $0.53. The company generated net revenue of $469 million, net income of $39 million, and Adjusted EBITDA of $73 million.
Same-unit revenue grew 6.4%, driven by a 3.5% increase in reimbursement-related factors and 2.9% growth in patient volume. Notably, NICU days increased by 6.0%. Based on strong performance, Pediatrix raised its full-year 2025 Adjusted EBITDA outlook to $245-255 million from the previous $220-240 million range.
The company maintains a solid financial position with $224.7 million in cash and cash equivalents, generating $138.1 million in cash from operations during Q2 2025. Total debt stands at $606 million, with no outstanding borrowings under its revolving credit facility.
Pediatrix Medical Group (NYSE:MD) has scheduled its 2025 second quarter earnings conference call and webcast for Tuesday, August 5, 2025, at 9:00 a.m. ET. The company will release detailed financial results through a press release before market open on the same day. Investors can access the webcast through the company's investor relations website at www.pediatrix.com/investors.
Pediatrix Medical Group (NYSE: MD) has appointed Dr. Kurt D. Newman as an independent director to its board, effective July 1, 2025. Dr. Newman is the former President and CEO of Children's National Hospital in Washington, D.C., where he served for 12 years, following a 25-year tenure as a pediatric surgeon.
Dr. Newman brings significant healthcare leadership experience, having been recognized as "CEO of the Year" by the Washington Business Journal in 2021 and inducted into the Washington Business Hall of Fame in 2023. He is known for fostering patient-centered care and innovation in pediatric healthcare, particularly in expanding mental health access for children.
Pediatrix Medical Group (NYSE: MD) reported strong Q1 2025 financial results, with earnings of $0.24 per share and Adjusted EPS of $0.33. The company generated net revenue of $458.4 million, net income of $21 million, and Adjusted EBITDA of $49.2 million. While total revenue decreased from $495.1 million in Q1 2024, same-unit revenue grew by 6.2%. Due to strong Q1 performance, Pediatrix raised its full-year 2025 Adjusted EBITDA guidance to $220-240 million, up from the previous $215-235 million range.
The company saw improvements in key metrics, including a 4.6% increase in same-unit reimbursement factors and a 1.6% rise in patient volume. NICU days increased by 2.0%, while office-based services grew 2.6%. The company ended Q1 2025 with $99 million in cash and total debt of $611 million.